文献速递间质性肺疾病肺栓塞与肺血管病

吸入曲前列尼尔剂量对间质性肺病相关肺动脉高压临床结局的影响

Inhaled Treprostinil Dosage in Pulmonary Hypertension Associated With Interstitial Lung Disease and Its Effects on Clinical Outcomes.
PubMed 文献 · Chest · 2022-09-15

本研究为INCREASE研究的事后分析,纳入16周双盲随机安慰剂对照试验中接受吸入曲前列尼尔(iTre)的间质性肺病相关肺动脉高压患者。按4周时每次吸入次数(<9次或≥9次)分组,评估临床恶化与临床改善。结果显示较高剂量组临床恶化事件更少、临床改善更多,支持早期启用并滴定至每日四次至少9次吸入。

要点

  • 4周时达到≥9次/次(每日四次)的iTre剂量与更少临床恶化相关。
  • 高剂量iTre组临床改善率高于低剂量组和安慰剂组。
  • 建议间质性肺病相关肺动脉高压患者早期启用并滴定iTre至至少9次/次每日四次。

核心结论

  • 较高剂量的吸入曲前列尼尔在预防临床恶化和实现临床改善方面总体显示更大获益。
  • 数据支持在间质性肺病相关肺动脉高压患者中早期启用并滴定至每日四次至少9次吸入的剂量。

研究设计与样本

  • INCREASE研究的事后分析,该研究为16周双盲、随机、安慰剂对照试验。
  • 根据4周时达到的每次吸入次数(<9次和≥9次)将患者分为四组:iTre高剂量组70例、iTre低剂量组79例、安慰剂高剂量组86例、安慰剂低剂量组67例。

主要发现

  • 第4至16周,iTre高剂量组17.1%和低剂量组22.8%发生临床恶化事件,安慰剂两组分别为33.7%和34.3%(P = .006)。
  • 至第16周,iTre高剂量组15.7%和低剂量组12.7%达到临床改善,安慰剂两组分别为7%和1.5%(P = .003)。

关键数值与推荐

  • 临床恶化定义为6分钟步行距离下降15%、心肺住院、肺移植或死亡。
  • 临床改善定义为6分钟步行距离增加15%且N末端脑钠肽前体降低30%,无任何临床恶化事件。

临床怎么用

  • 对间质性肺病相关肺动脉高压患者,可考虑早期启用吸入曲前列尼尔并滴定至每日四次至少9次吸入。

局限性

  • 本研究为事后分析,分组基于4周时达到的吸入次数,非随机分配。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pulmonary hypertension (PH) complicates the course of many patients with fibrotic interstitial lung disease (ILD). Inhaled treprostinil (iTre) has been shown to improve functional ability and to delay clinical worsening in patients with PH resulting from ILD. RESEARCH QUESTION: Do higher dosages of iTre have greater benefits in preventing clinical worsening and achieving clinical improvement? STUDY DESIGN AND METHODS: Post hoc analysis of the INCREASE study, a 16-week double-blind, randomized, placebo-controlled trial of iTre in patients with PH resulting from ILD. Four groups were identified based on the number of breaths per session (bps; < 9 and ≥ 9 bps) of active drug or placebo attained at 4 weeks. Patients were evaluated for clinical worsening (15% decrease in 6-min walkdistance, cardiopulmonary hospitalization, lung transplantation, or death) or clinical improvement (15% increase in the six-minute walk distance with a concomitant 30% reduction in N-terminal prohormone of brain natriuretic peptide without any clinical worsening event). RESULTS: At 4 weeks, 70 patients were at a dose of ≥ 9 bps (high-dosage group) and 79 patients were at a dose of < 9 bps (low-dosage group) in the iTre arm vs 86 patients in the high-dose group and 67 patients in the low-dose group in the placebo arm. Between weeks 4 and 16, 17.1% of patients in the high-dose treprostinil group and 22.8% in the low-dose treatment group experienced a clinical worsening event vs 33.7% and 34.3% of patients in the two placebo arms, respectively (P = .006). By week 16, 15.7% and 12.7% of patients in the high- and low-dose iTre groups, respectively, demonstrated clinical improvement vs 7% and 1.5% patients in the placebo arms (P = .003) INTERPRETATION: Higher dosages of iTre overall show greater benefit in terms of preventing clinical worsening and achieving clinical improvement. These data support the early initiation and uptitration of therapy to a dosage of at least 9 bps four times daily in patients with PH resulting from ILD. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT02630316; URL: www. CLINICALTRIALS: gov.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Nathan SD, Deng C, King CS, et al. Inhaled Treprostinil Dosage in Pulmonary Hypertension Associated With Interstitial Lung Disease and Its Effects on Clinical Outcomes. Chest. 2022. PMID: 36115497. doi:10.1016/j.chest.2022.09.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。